Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07586501
Enrolling by invitation Observational

China-NINE Cohort：Neuroimmune Network in Elderly / Neurodegeneration

NCT07586501 · tracked via the Priya Life Science China tracker
Sponsor
Yantai Yuhuangding Hospital
Phase
Observational
Started
2026-01-16
Last updated
2026-05-14

Condition(s) studied

Cognitive DysfunctionCognitive Dysfunction, Cognitive DisorderParkinson's Disease (PD)

Study summary

This is an observational study aimed at understanding the cognitive, functional, and behavioral characteristics of Chinese patients with cognitive impairment, exploring the underlying mechanisms, and providing evidence for early diagnosis, treatment, and care of cognitive disorders including dementia.

Eligible participants will undergo a series of assessments and examinations, including cognitive and memory scale tests, routine blood tests, ApoE genetic testing, cerebrospinal fluid testing, brain MRI, functional MRI, and FDG-PET/AV45-PET scans when necessary. Additional samples such as saliva, nasal secretions, and stool may also be collected. Most evaluations are provided free of charge to support diagnosis and treatment guidance.

Participation is voluntary. All personal information and research data will be kept confidential. Potential benefits include access to expert clinical care and free cognitive assessments for disease evaluation. Possible inconveniences include time commitment and temporary discomfort during examinations; medical support will be provided if needed.

Eligibility

Sex
ALL
Min age
55 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Participants with clinically diagnosed cognitive impairment. Patients with clinically diagnosed Parkinson's disease. Healthy control participants. Exclusion Criteria: * Central nervous system infection, head trauma, epilepsy, multiple sclerosis, or other major neurological disorders. Malignant tumors. Family history of genetic disorders.

Primary outcome measure(s)

  • Degree and Type of Cognitive Impairment Assessed by Neuropsychological Scales — From enrollment to the end of treatment at 3 years
    Higher scores indicate better cognitive function; lower scores indicate more severe cognitive impairment.

Trial sites (2)

FacilityCityRegionStatus
Yantai Yuhuangding Hospital Yantai Shandong
Yantai Yuhuangding Hospital Yantai China

More Yantai Yuhuangding Hospital trials in China

A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC) Starting soon
A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC Recruiting

Other trials for the same condition

Shanghai Clinical Cohort - Parkinson's Disease (Reserve) Recruiting
Study on Aging and Cognitive Impairment in China Recruiting
The Association Between Primary Aldosteronism and Cognitive Dysfunction Recruiting
Effects of Adaptive Difficulty Computerized Cognitive Training on Cognitive Function Improvement in Older Adults With Mild Cognitive Impairment Starting soon
Immediate Effects of External Trigeminal Nerve Stimulation on Motor Dysfunction in Parkinson's Disease Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07586501 on ClinicalTrials.gov ↗ ← All trials in China